Christal Mickle
Founder chez ZEVRA THERAPEUTICS, INC.
Fortune : 772 508 $ au 31/03/2024
Profil
Christal M.
M.
Mickle is the founder and the Chief Development Officer at Zevra Therapeutics, Inc., a company founded in 2006.
Prior to her current position, she worked as a Research Associate at New River Pharmaceuticals, Inc. from 2002 to 2005.
Ms. Mickle holds a graduate degree from the University of Virginia, which was conferred in 2005, and an undergraduate degree from Virginia Polytechnic Institute & State University, which was conferred in 2001.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
ZEVRA THERAPEUTICS, INC.
0,32% | 22/03/2024 | 133 191 ( 0,32% ) | 772 508 $ | 31/03/2024 |
Postes actifs de Christal Mickle
| Sociétés | Poste | Début |
|---|---|---|
| ZEVRA THERAPEUTICS, INC. | Founder | 30/10/2006 |
Anciens postes connus de Christal Mickle
| Sociétés | Poste | Fin |
|---|---|---|
New River Pharmaceuticals, Inc.
 New River Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology New River Pharmaceuticals, Inc. develops pharmaceutical products. Its product candidates in clinical development are an amphetamine derivative (NDA filed) and an opioid derivative that they believe will provide alternatives to marketed drugs. The company was founded by Randal J. Kirk in 1996 and is headquartered in Radford, VA. | Corporate Officer/Principal | 01/01/2005 |
Formation de Christal Mickle
| University of Virginia | Graduate Degree |
| Virginia Polytechnic Institute & State University | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| ZEVRA THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 1 |
|---|---|
New River Pharmaceuticals, Inc.
New River Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology New River Pharmaceuticals, Inc. develops pharmaceutical products. Its product candidates in clinical development are an amphetamine derivative (NDA filed) and an opioid derivative that they believe will provide alternatives to marketed drugs. The company was founded by Randal J. Kirk in 1996 and is headquartered in Radford, VA. | Health Technology |
